George Eng
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Viral-associated cancers and disorders
- Advanced biosensing and bioanalysis techniques
- Animal Virus Infections Studies
- Studies on Chitinases and Chitosanases
- Monoclonal and Polyclonal Antibodies Research
- RNA Interference and Gene Delivery
- RNA modifications and cancer
- Extracellular vesicles in disease
- T-cell and Retrovirus Studies
- Cancer Genomics and Diagnostics
- Chromosomal and Genetic Variations
- Circular RNAs in diseases
- Galectins and Cancer Biology
- Chemokine receptors and signaling
- interferon and immune responses
- Cell Adhesion Molecules Research
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
Mass General Brigham
2023
Harvard University
2023
Massachusetts Institute of Technology
2023
Abstract Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element overexpressed in carcinomas high-risk precursors during carcinogenesis with negligible expression normal tissues, suggesting ORF1p could...
<p>Calibration curves for “3rd Generation” Simoa assays.</p>
<p>Additional second-generation ORF1p Simoa assay measurements in healthy and cancer patients.</p>
<p>Assay validation for second-generation ORF1p Simoa assays.</p>
<p>Kaplan-Meier Survival Analysis by ORF1p.</p>
<p>Assay validation for second-generation ORF1p Simoa assays.</p>
<p>Screening of multimeric nanobodies for ORF1p detection with Simoa.</p>
<p>Circulating ORF1p levels in patients with IPMN</p>
<p>Circulating ORF1p levels in lung cancer patient cohort</p>
<p>Screening of newly developed monoclonal antibody candidates.</p>
<p>Additional second-generation ORF1p Simoa assay measurements in healthy and cancer patients.</p>
<p>Second round of screening newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma.</p>
<div>Abstract<p>Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element overexpressed in carcinomas high-risk precursors during carcinogenesis with negligible expression normal tissues,...
<p>(obtained from Drapkin Lab at the University of Pennsylvania).Circulating CA125 and HE4 levels, as measured by Simoa, in ovarian cancer patient cohort.</p>
<p>Nanobody generation</p>
<p>Calibration curves for “3rd Generation” Simoa assays.</p>
<p>Engineered Nanobody constructs.</p>
<p>First round of screening newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma.</p>
<p>First round of screening newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma.</p>
<p>Genomics analysis of lung cancer patient cohort.</p>
<p>Kaplan-Meier Survival Analysis by ORF1p.</p>
<p>Circulating ORF1p levels in breast cancer patients.</p>
<p>Second round of screening newly developed “3rd generation” assays using dimeric nanobody detectors.</p>
<p>Circulating ORF1p levels in eight stage I ovarian cancer patients</p>